Syndax (SNDX) Q1 2026 earnings review
Operating Leverage Shines, But Commercial Growth Decelerates Sequentially
Syndax delivered a textbook demonstration of operating leverage in 26Q1. Total revenue surged 224% YoY to $64.9M, while operating expenses actually declined YoY, slashing the net loss in half to $42.7M. The path to profitability is clearly visible and mathematically sound based on current guidance. However, underneath the stellar YoY comparisons, the sequential momentum of both commercial assets is cooling. Niktimvo net sales reversed, dipping slightly from 25Q4, while Revuforj's sequential growth decelerated from 38% to 11%. Management's ability to re-accelerate these products in their current indications will dictate the stock's near-term trajectory while investors wait for frontline trial data.
🐂 Bull Case
Total revenues more than tripled YoY ($20M to $64.9M), while operating expenses shrank 4% YoY. This fixed-cost dynamic means incremental sales flow powerfully to the bottom line, thoroughly de-risking the balance sheet.
Revuforj is unlocking a durable revenue stream as post-transplant maintenance use increases. Nearly 50% of KMT2A patients now proceed to stem cell transplants (up from 33%), creating a long-tail recurring revenue base.
🐻 Bear Case
Despite management touting 'significant growth' YoY, Niktimvo net sales actually declined sequentially ($55.1M in 26Q1 vs $56.0M in 25Q4). The initial bolus of pent-up demand in 3L+ cGVHD may have been fully absorbed.
Revuforj growth decelerated sharply to 11% QoQ (from 38% QoQ in 25Q4). While still growing, the rapid market penetration phase in the R/R NPM1m setting might be slowing faster than modeled.
⚖️ Verdict: ⚪
Neutral. The financial mechanics—flat OpEx against growing revenue—are aggressively bullish. However, the sequential plateauing of the two core commercial products contradicts the hyper-growth narrative and demands a 'show me' approach for Q2.
Key Themes
Operating Leverage Kicking In
Accelerating. Syndax achieved a major inflection point in corporate maturation: scaling revenues without scaling costs. 26Q1 R&D and SG&A expenses totaled $96.4M, notably down from $102.6M in 25Q1, driven by reduced launch and milestone costs. This fixed-cost dynamic allows the $15.9M high-margin Niktimvo collaboration revenue to drop straight to the bottom line, drastically reducing the cash burn.
Niktimvo Sequential Revenue Reversal
Reversing. Management highlighted Niktimvo's massive YoY growth, but deliberately omitted the sequential comparison in the press release text. Partner Incyte reported $55.1M in 26Q1 Niktimvo net sales, which is a decline from the $56.0M reported in 25Q4. This contradicts the narrative of a continuously compounding launch and raises concerns about peak penetration in the 3L+ cGVHD market.
Revuforj Growth Rate Decelerating
Decelerating. Revuforj net revenue of $48.9M represented an 11% sequential increase. While technically growing, this is a sharp deceleration from the 38% sequential jump seen in 25Q4 following the NPM1m label expansion. The prescription volume grew 13% QoQ, mirroring the revenue, suggesting the low-hanging fruit in the R/R setting has been captured.
Post-Transplant Duration Extension
Stable. The commercial usage patterns for Revuforj are yielding better-than-trial dynamics. Recent data shows that nearly 50% of R/R KMT2A patients are now proceeding to hematopoietic stem cell transplant (HSCT), up from previous estimates of 33%. Because a large portion of these patients resume Revuforj post-transplant as maintenance therapy, the average duration of treatment per patient is structurally extending, boosting lifetime value.
Aggressive Frontline Expansion via EVOLVE-2 and REVEAL-ND
Accelerating. The largest long-term value driver remains the >$5B frontline (1L) AML market. Syndax is successfully enrolling the pivotal Phase 3 EVOLVE-2 trial (combining Revuforj with venetoclax/azacitidine for unfit patients) and the Phase 3 REVEAL-ND trial (combining with intensive chemotherapy for fit NPM1m patients). Being first-to-market in the frontline setting represents the ultimate moat for the franchise.
Execution Risk in Frontline Clinical Paradigm
Stable. While moving into 1L is highly lucrative, it carries immense execution risk. Moving from a monotherapy in a relapsed setting to a combination therapy (like with intensive 7+3 chemotherapy) in newly diagnosed patients introduces complex tolerability challenges. Any safety signals in these pivotal trials would severely derail the long-term TAM expectations.
Other KPIs
Down sequentially from $394.1M at the end of 2025. The implied cash burn for the quarter was roughly $42M, aligning perfectly with the reported net loss. With an accelerating top line and capped expenses, this cash position is highly robust and fully supports management's claim of reaching profitability without further dilution.
Represents Syndax's 50% share of Niktimvo's net commercial profit (Incyte's reported net sales minus cost of sales and commercial expenses). This equated to an effective 28.8% margin on the $55.1M in end-user sales, demonstrating the high profitability of this partnered asset.
Guidance
Stable. This guidance excludes approximately $50M in non-cash stock compensation. The 26Q1 combined cash OpEx was $96.4M ($58.8M R&D + $37.6M SG&A), placing them exactly on a $385M-$395M annualized run rate. This confirms that management is executing flawlessly on their promise to hold the operating expense base flat.
Key Questions
Niktimvo QoQ Decline
Niktimvo net sales declined from $56M in 25Q4 to $55.1M in 26Q1. Was this driven by typical Q1 gross-to-net headwinds, seasonal inventory destocking, or have we reached peak penetration of the initial bolus of 3L+ cGVHD patients?
Revuforj Indication Mix
With the 11% sequential growth in Revuforj, can you parse out the current sales split between the NPM1m and KMT2Ar indications? Is KMT2Ar completely flat, leaving NPM1m to drive all the incremental growth?
HSCT Maintenance Restart Rates
You noted that nearly 50% of KMT2A patients are going to transplant. What exact percentage of those transplanted patients are successfully resuming Revuforj post-engraftment, and what is the current average duration for those maintenance patients?